KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $756.0 million.

  • Acadia Pharmaceuticals' Cash & Current Investments rose 49.83% to $847.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 54.21%. This contributed to the annual value of $756.0 million for FY2024, which is 72.26% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Cash & Current Investments is $756.0 million, which was up 72.26% from $438.9 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Cash & Current Investments ranged from a high of $756.0 million in FY2024 and a low of $416.8 million during FY2022.
  • Its 3-year average for Cash & Current Investments is $537.2 million, with a median of $438.9 million in 2023.
  • In the last 5 years, Acadia Pharmaceuticals' Cash & Current Investments dropped by 19.95% in 2022 and then skyrocketed by 72.26% in 2024.
  • Acadia Pharmaceuticals' Cash & Current Investments (Yearly) stood at $632.0 million in 2020, then declined by 17.60% to $520.7 million in 2021, then fell by 19.95% to $416.8 million in 2022, then rose by 5.29% to $438.9 million in 2023, then surged by 72.26% to $756.0 million in 2024.